drugset / Trial / NCT02536170

Arginine Therapy for Sickle Cell Disease Pain

NCT02536170

RandomizedParallel-groupDouble-blindTreatment

Summary

The aim of this study is to determine whether giving extra arginine, a simple amino acid, to patients with sickle cell disease seeking treatment for a pain crisis (vaso-occlusive painful events (VOE) will decrease pain scores, decrease the need for pain medications or decrease length of hospital stay or emergency department visit. Funding Source - FDA OOPD.

Timeline

Start
2016-02
Primary completion
2021-02-21
Completion
2021-02-21

Drugs

EvaluationDrugModalityDoseRoute
Subject L-arginine Small molecule 100 mg/kg Intravenous

Indications